The main purpose of the NOPSAD collection is to aggregate standardised jurisdictional data on the number of clients accessing pharmacotherapy for the treatment of opioid dependence, the number of prescribers participating in the delivery of pharmacotherapy treatment, and quantitative information about the prescribing sector, enabling national information on pharmacotherapy to be reported.

Collection details

Temporal coverage

from 30 June 2004 to 30 June 2017

Geographical coverage

National and state and territory

Data availability

  • Publications
  • Summary tables published in electronic form
  • Statistics
  • Client specified tables on request which may be subject to data provider approval (charges apply)
  • Unit records not available

Data scope

Covers provision of opioid pharmacotherapy treatment, practitioners who prescribe the treatment, dosing sites who dispense the pharmacotherapy drugs, and clients receiving the opioid pharmacotherapy treatment. Pharmacotherapies currently recommended for treatment of opioid dependency:

  • Methadone hydrochlorideMethadone Syrup®
  • Biodone Forte®, BuprenorphineSubutex®
  • Buprenorphine/NaloxoneSuboxone®.

Methodology

Admin data

Metadata information and data quality statement (DQS)

NOPSAD 2017 DQS

External links and information

NOPSAD 2017

Alcohol and Other Drug Treatment Services in Australia 2016–17   

Contact

[email protected]